BioSpace News Archive

Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD)

Shoulder Innovations, an emerging leader in the development of shoulder replacement systems, announced that it has signed an exclusive license agreement for Genesis Software Innovation’s “GSI” PreView Shoulder™ Arthroplasty Planning Software, which recently achieved FDA 510 clearance.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced it will host its second virtual Research & Development event on Monday, May 17, 2021, from 9:30 to 11:30 a.m., Eastern Time.

Galafold® (migalastat) PerformanceReflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M

TG Therapeutics, Inc. announced its financial results for the first quarter ending March 31, 2021 and recent company developments, along with a business outlook for 2021.

One kit provides comprehensive, reproducible detection of variants for diagnostics and carrier screening using a simple workflow that produces results in less than four hours

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that it has expanded its research collaboration with Johns Hopkins University to include studies investigating the biology of a novel myeloid target that was computationally-discovered by Compugen.

Insmed Incorporated announced that it intends to offer and sell $250 million of its common stock and $500 million aggregate principal amount of its convertible senior notes due 2028 in separate concurrent underwritten public offerings, a portion of which will be used to repurchase Insmed’s existing outstanding convertible senior notes due 2025.

NEAA’s current estimated annualized revenue run-rate is approximately US$3.6 million with operating EBITDA(1) margins equal to approximately 40% which is generally consistent with other similar acquisitions made by CRH.

New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease